A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease
Public ClinicalTrials.gov record NCT00284804. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Multicenter, Phase II Study of MDX-060 in Combination With Gemcitabine, MDX060 in Combination With Dexamethasone, and Gemcitabine Monotherapy in Patients With Relapsed or Refractory Hodgkin's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to determine the objective response rate in patients with relapsed or refractory Hodgkin's disease treated with MDX-060 in combination with gemcitabine or gemcitabine alone.
Study identification
- NCT ID
- NCT00284804
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 74 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2005 (Type not available)
- Primary completion
- May 2008 (Actual)
- Completion
- Oct 2009 (Actual)
- Last update posted
- Oct 12, 2015
2005 – 2009
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope, National Medical Center | Duarte | California | 91010 | — |
| California Oncology of the Central Valley | Fresno | California | 93710 | — |
| University of California, San Diego/Moores UCSD Cancer Center | La Jolla | California | 92093-0698 | — |
| H. Lee Moffitt Cancer & Research Institute | Tampa | Florida | 33612 | — |
| Rush Cancer Institute | Chicago | Illinois | 60612 | — |
| St. Francis Hospital Center | Beech Grove | Indiana | 46107 | — |
| American Health Network of Indiana | Indianapolis | Indiana | 46237 | — |
| Division of Hematology/Oncology, Tufts-New England Medical Center | Boston | Massachusetts | 02111 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| The Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Roswell Park Cancer Center | Buffalo | New York | 14263 | — |
| Mount Sinai School of Medicine | New York | New York | 10029 | — |
| Carolina BioOncology Institute, PLLC | Huntersville | North Carolina | 28078 | — |
| M.D. Anderson Cancer Center, The University of Texas | Houston | Texas | 77030 | — |
| Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506-9162 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00284804, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 12, 2015 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00284804 live on ClinicalTrials.gov.